Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Clin Infect Dis ; 79(1): 56-59, 2024 Jul 19.
Artigo em Inglês | MEDLINE | ID: mdl-38642403

RESUMO

Among a statewide cohort of 1874 patients surviving hospitalization for drug use-associated endocarditis during 2017-2020, the 3-year risk of death or future hospitalization was 38% (16% for death before later infection, 14% for recurrent endocarditis, 14% for soft tissue, 9% for bacteremia, 5% for bone/joint, and 4% for spinal infections).


Assuntos
Endocardite , Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Endocardite/mortalidade , Fatores de Risco , Hospitalização/estatística & dados numéricos , Bacteriemia/mortalidade , Endocardite Bacteriana/mortalidade , Idoso , Estudos de Coortes , Transtornos Relacionados ao Uso de Substâncias/complicações , Transtornos Relacionados ao Uso de Substâncias/mortalidade
2.
Epidemiology ; 35(1): 7-15, 2024 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-37820243

RESUMO

BACKGROUND: Severe skin and soft tissue infections related to injection drug use have increased in concordance with a shift to heroin and illicitly manufactured fentanyl. Opioid agonist therapy medications (methadone and buprenorphine) may improve long-term outcomes by reducing injection drug use. We aimed to examine the association of medication use with mortality among people with opioid use-related skin or soft tissue infections. METHODS: An observational cohort study of Medicaid enrollees aged 18 years or older following their first documented medical encounters for opioid use-related skin or soft tissue infections during 2007-2018 in North Carolina. The exposure was documented medication use (methadone or buprenorphine claim) in the first 30 days following initial infection compared with no medication claim. Using Kaplan-Meier estimators, we examined the difference in 3-year incidence of mortality by medication use, weighted for year, age, comorbidities, and length of hospital stay. RESULTS: In this sample, there were 13,286 people with opioid use-related skin or soft tissue infections. The median age was 37 years, 68% were women, and 78% were white. In Kaplan-Meier curves for the total study population, 12 of every 100 patients died during the first 3 years. In weighted models, for every 100 people who used medications, there were four fewer deaths over 3 years (95% confidence interval = 2, 6). CONCLUSION: In this study, people with opioid use-related skin and soft tissue infections had a high risk of mortality following their initial healthcare visit for infections. Methadone or buprenorphine use was associated with reductions in mortality.


Assuntos
Buprenorfina , Transtornos Relacionados ao Uso de Opioides , Infecções dos Tecidos Moles , Adulto , Feminino , Humanos , Masculino , Analgésicos Opioides/efeitos adversos , Buprenorfina/uso terapêutico , Hospitalização , Metadona/uso terapêutico , Tratamento de Substituição de Opiáceos , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Infecções dos Tecidos Moles/complicações , Infecções dos Tecidos Moles/tratamento farmacológico , Adolescente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA